About Jonas Hink

This author has not yet filled in any details.
So far Jonas Hink has created 14 blog entries.

Political courage to boost the life science industry?

2024-01-16T13:08:22+01:00

There is a recognition from the government of the crucial role of the life science sector in the Danish economy, including through the export of pharmaceuticals, and there is a strong appetite to create more growth stories like Novo Nordisk.

Political courage to boost the life science industry?2024-01-16T13:08:22+01:00

Is – or can Denmark become – a leading life science nation?

2024-01-16T12:34:00+01:00

If the pattern of the majority of life science funding in Denmark going to early stages continues, alternative financing options need to be established for more mature companies that require long-term investments to scale up and realize their potential in Denmark.

Is – or can Denmark become – a leading life science nation?2024-01-16T12:34:00+01:00

Disease burdens, clinical studies, and investments – is there proportionality?

2023-11-03T14:55:01+01:00

The reasons for the disparity between the extent of clinical drug research and the disease burden likely vary for different diseases. However, there are probably some common factors, including the ability and willingness to pay or lack thereof, and thus the expected return associated with investment. In these cases, it makes sense to establish commercial incentives for research and development in under-prioritized disease areas.

Disease burdens, clinical studies, and investments – is there proportionality?2023-11-03T14:55:01+01:00

Unnecessary treatments, redundant medicines, or ill-advised decisions?

2023-10-16T12:55:49+02:00

The ongoing discussion about initiatives that can counteract and reduce unnecessary treatments and treatments with low value is also relevant for new medicines. One of the dilemmas here is the weighing of the relationship between the clinical significance of a drug and the costs of treatment with the drug.

Unnecessary treatments, redundant medicines, or ill-advised decisions?2023-10-16T12:55:49+02:00

Will it be possible to use AI for generation of scientific and clinical evidence that is currently demonstrated via traditional randomized controlled trials?

2023-09-13T17:17:43+02:00

There are many questions related to the development, limitations and validity of AI and machine learning applied to healthcare solutions and products. Despite various challenges such as dataset shifts and automation bias, one can envision a future where AI-generated data is used to document clinical safety and efficacy, thereby replacing the randomized controlled trials as we know them today. This would lead to a massive acceleration in the development of new healthcare solutions and products. However, there is still a way to go. Another and perhaps more realistic scenario is broader use of AI-supported clinical research and drug development, where AI and machine learning become an integrated tool for faster and less expensive development of safer and more efficacious healthcare solutions and products. It could be for accurate and comprehensive prediction of desired and unwanted effects, individual disease development, risk profile and prognosis, as well as for identifying which patients will benefit the most from new therapies, and allocation to the optimal treatment offer.

Will it be possible to use AI for generation of scientific and clinical evidence that is currently demonstrated via traditional randomized controlled trials?2023-09-13T17:17:43+02:00

Voucher proposal from the EU Commission is a potential game changer

2023-09-13T20:36:12+02:00

Everyone agrees that antimicrobial resistance (AMR) poses a growing global health threat, but no one wants to foot the bill for the development of new types of antibiotics. However, with the EU Commission's proposal to revise EU pharmaceutical legislation, there is hope on the horizon. The allocation of a voucher that the recipient can sell at a high price will significantly change the situation.

Voucher proposal from the EU Commission is a potential game changer2023-09-13T20:36:12+02:00

Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice

2023-08-18T14:30:38+02:00

Abstract Antibiotic treatments have detrimental effects on the microbiome and lead to antibiotic resistance. To develop a phage therapy against a diverse range of clinically relevant Escherichia coli, we screened a library of 162 wild-type (WT) phages, identifying eight phages with broad coverage of E. coli, complementary binding to bacterial surface receptors, and the capability to stably carry inserted cargo. Selected phages were engineered with tail fibers and CRISPR–Cas machinery to specifically target E. coli. We show that engineered phages target bacteria in biofilms, reduce the emergence of phage-tolerant E. coli and out-compete their ancestral WT phages in coculture experiments. A combination of the four most complementary bacteriophages, called SNIPR001, is well tolerated in both mouse models and minipigs and reduces E. coli load in the mouse gut better than its constituent components separately. SNIPR001 is in clinical development to selectively kill E. coli, which may cause fatal infections in hematological cancer patients.

Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice2023-08-18T14:30:38+02:00

Dear EU Commission – think carefully

2023-11-03T14:56:54+01:00

There is a lot at stake as the EU Commission presents its proposals for the revision of the general pharmaceutical legislation, as well as the legislation concerning medicines for children and rare diseases. These proposals follow the EU Commission's previously announced pharmaceutical strategy for Europe.

Dear EU Commission – think carefully2023-11-03T14:56:54+01:00

Don’t forget the rare but collectively common diseases

2023-11-03T14:59:08+01:00

There are significant human and societal gains to be made through rapid, accurate, and effective diagnosis and treatment of the 6-8% of the population living with a rare disease.

Don’t forget the rare but collectively common diseases2023-11-03T14:59:08+01:00
Go to Top